Fox News Digital reached out to GLP-1 manufacturers requesting comment.
Discontinuation of GLP-1RAs in patients with metabolic syndrome can have significant implications including weight regain, worsening glycemic control and increased cardiovascular risks, and can lead to potential withdrawal symptoms
Dont be hard on yourself, this isnt a character flaw - its often a biochemical lag
During that time, the FDA used enforcement discretion, meaning it generally didnt crack down on sellers while the peptides were being evaluated
The post hoc analysis of pooled data from the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 2, 3, and 5 trials indicated that semaglutide treatment at 2.4 mg did not increase the risk of depressive symptoms or suicidal ideation compared to placebo, while demonstrating a statistically significant yet clinically negligible decrease in depressive symptoms [75]